Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.
A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.
Medivir AB did not have earnings to cover the interest expense.
Medivir AB's debt to revenue ratio for the quarter that ended in Jun. 2026 was 0.92.
As of today, Medivir AB's Altman Z-Score is 15.00.
Medivir AB (STU:MVR0) Financial Strength Explanation
The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.
Medivir AB has the Financial Strength Rank of 7.
Medivir AB Financial Strength Related Terms
STU:MVR0 vs VRTX, REGN, MRNA: Financial Strength Comparison
For the Biotechnology subindustry, Medivir AB's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medivir AB Financial Strength vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medivir AB's Financial Strength distribution charts can be found below:
* The bar in red indicates where Medivir AB's Financial Strength falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Medivir AB has a Z-score of 15.00, indicating it is in Safe Zones. This implies the Z-Score is strong.
Good Sign:
Altman Z-score of 15 is strong.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medivir AB (STU:MVR0) has a Financial Strength of 7 as of Jun. 2026. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Medivir AB and its competitors. This is near median its historical median of 7.00. Over the past decade, Medivir AB's Financial Strength has ranged from 3.00 to 10.00.
Is Medivir AB's Financial Strength too high?
Medivir AB's current Financial Strength of 7 is near median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 10.00. Overall, Medivir AB has a GF Score™ of 52/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medivir AB's Financial Strength compare to VRTX and REGN?
Medivir AB's Financial Strength of 7 can be compared against companies in the Biotechnology industry. Historically, Medivir AB's own Financial Strength has ranged from 3.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Financial Strength for a Biotechnology company?
A good Financial Strength depends on the Biotechnology industry context. However, Financial Strength should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Financial Strength mean?
A high Financial Strength can signal that a stock is expensive relative to its fundamentals. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Medivir AB and its competitors. Medivir AB's current Financial Strength is 7, which is near median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medivir AB stock overvalued right now?
Based on GuruFocus' analysis, Medivir AB (STU:MVR0) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.11, compared to a current price of €0.14 — trading 29.3% above its estimated fair value. The current Financial Strength is 7, which is near median its 10-year median of 7.00. Medivir AB's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Financial Strength calculated?
Financial Strength is calculated from a company's financial statements. For Medivir AB (STU:MVR0), the current Financial Strength is 7 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medivir AB (STU:MVR0) Overvalued in 2026?
Based on GuruFocus' analysis, Medivir AB stock appears to be overvalued.
The current stock price of €0.14 is trading 29.3% above its estimated GF Value™ of €0.11.
GuruFocus considers Medivir AB to be Modestly Overvalued.
Key valuation signals for STU:MVR0:
Financial Strength: 7 (near median its 10-year median of 7.00)
GF Value™: €0.11 vs. price of €0.14 (29.3% above fair value)
No single metric tells the full story. See the STU:MVR0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also also has four out-licensed projects Xerclear, MIV-701, MBLI/MET-X. Geographically, it generates its maximum revenue from Europe and other regions.
52GF Score
Get the complete analysis for STU:MVR0
Financial Strength is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:MVR0 has been successfully added to your 
